Subject Index, Volume 5

A
Absolute risk reduction, usage of, 430
Abstracts
  ISPOR Fifth Annual European Congress, 443
  ISPOR Seventh Annual International Meeting, 117
Activity impairment, gastroesophageal reflux disease and, 106
Advertising claims
  misleading/unsubstantiated, 389
  regulation of patient-reported outcomes and, 372
Airways Questionnaire, for COPD quality-of-life assessment, 436
Anti-hypertensive drug therapy, cost-effectiveness analyses, 359
Aspergillosis, incidence and direct costs of, 27

B
Bias against new innovations, in willingness-to-pay valuations, 67
Bootstrap confidence levels, for diabetes management costs, 397

C
Candidiasis, incidence and direct costs of, 27
Ceiling effect, HRQL measures and, 329
Censored LAD model, vs. other HRQL measures, 329
Chronic obstructive pulmonary disease, comparative analysis of QoL measures, 436
Clinical trials. See also specific clinical trials
  analytic issues, 19
  HRQL measures, selection of, 16
  study design, 18
  CODE-2 (Costs of Diabetes in Europe-Type 2 study), 397
Colorectal cancer metastatic, inpatient care, cost-analysis of, 35
Company perspective, of pharmacogenetic testing, 10
COPD, comparative analysis of QoL measures, 436
Cost-analysis, of metastatic colorectal cancer inpatient care, 35
Cost-benefit analysis, vs. cost-effectiveness analysis, 338
Cost-effectiveness analysis
  of anti-hypertensive drug therapy, 359
  of CMV management in liver transplant patients, 347
  of GERD long-term management, 312
  of hepatitis B alternative therapy, 404
  of interferon beta for multiple sclerosis, 44
  of multiple sclerosis, 1
  in Stroke Outcome Model development, 82
  utility of, 71
  vs. cost-benefit analysis, 338
Cost-of-illness studies, multiple sclerosis, 1
Costs of Diabetes in Europe-Type 2 study (CODE-2), 397
Cost-utility analysis, gastroesophageal reflux disease, 312
Cryptococcosis, incidence and direct costs of, 27
Cytomegalovirus management, in liver transplant patients, decision making for, 347

D
Decision making
  for anti-hypertensive drug therapy, 359
  CMV management in liver transplant patients, 347
  impact of economic evaluations on, 71
  statistical analysis for, 430
Diabetes management costs, bootstrap confidence levels for, 397
Direct costs
  infantile respiratory syncytial virus infection, 55
  systemic fungal infections, 26
Disability, in Stroke Outcome Model development, 82
Drug benefit design, for formulary development, 382
Drug promotions
  FDA actions against misleading/unsubstantiated claims, 389
  of HRQL measures, 23
  patient-reported outcomes and, 372
  standardization of patient-reported outcomes and, 372

E
Economic evaluation
  gastroesophageal reflux disease, 312
  impact on decision making, 71
  of multiple sclerosis treatment, 1
  in Stroke Outcome Model development, 82
Economic violations, FDA actions against, 389

F
Family financial burden, infantile respiratory syncytial virus infection, 55
FDA. See Food and Drug Administration
Federal Food, Drug, and Cosmetic Act (FFDCA), 14
5-Fluorouracil toxicity, hospitalization costs, 3, 35
Subject Index

Food and Drug Administration (FDA)
- misleading/unsubstantiated advertising claims and, 389
- regulation of product labels and advertising claims, 372
Formulary development
- Kaiser-Permanente, 382
- Regence BlueShield, 297
France, Stroke Outcome Model development costing method, 95
Fungal infections, incidence and direct costs, 27
5-FU toxicity, hospitalization costs, 3, 35

G
Gastroesophageal reflux disease (GERD)
- long-term management, 312
- work productivity and activity impairment, 106
Gene therapy, development, 6
Genomics, economic issues, 5
Germany, Stroke Outcome Model development costing method, 95

H
Health-related quality of life (HRQL)
- analysis methods, comparison of, 329
- patient-reported outcomes, 295, 372
- regulatory issues, 14
Health Utilities Index, vs. other HRQL measures, 329
Heartburn. See Gastroesophageal reflux disease
Hepatitis B alternative therapy, cost-effectiveness analysis, 404
Histoplasmosis, incidence and direct costs of, 27
Hormone replacement therapy, time-trade-off assessments, 98
Hospital inpatient uniform bills, sepsis coding on, 79
Hospitalization costs
- for 5-FU toxicity, 35
- for infantile respiratory syncytial virus infections, 55
- of systemic fungal infections, 27
- for vertebral fractures, 301
HRQL. See Health-related quality of life
Hypertension treatment decision making, cost-effectiveness analyses for, 359

I
ICD-9-CM sepsis diagnostic codes, on UB-92 hospital bills, 79
Indirect costs
- of gastroesophageal reflux disease, 106
- infantile respiratory syncytial virus infection, 55
Innovation, WTP and WTA valuations, 67
Interferon cost-effectiveness
- for hepatitis B, 404
- for multiple sclerosis, 44

K
Kaiser-Permanente formulary development, 382

L
Lamivudine, cost-effectiveness for hepatitis B, 404
Length-of-stay, for vertebral fractures, 301
Liver transplantation CMV management, modeling of, 347
Long-term care costs
- in Stroke Outcome Model development, 82
- for vertebral fractures, 301

M
Markov process analysis, interferon beta in multiple sclerosis, 44
Migraine headaches, validation of patient perception questionnaire, 421
Mortality, in Stroke Outcome Model development, 82
Multiple sclerosis
- interferon beta cost-effectiveness, 44
- treatment evaluation, economic modeling studies for, 1

N
Naratriptan migraine therapy, patient perceptions of, 421
Nebacumab, Pharmacogenetic testing, 10
NHS Economic Evaluation Database, for decision-making and, 65, 71
Notices of violation, analysis of, 389

O
Odds ratio, usage of, 430
Orphan drugs, 7
Osteoporosis
- time-trade-off assessments, 98
- vertebral fractures, health care costs for, 301
Outcomes research, results-driven, 3

P
Patient Perception of Migraine Questionnaire (PPMQ), validation of, 421
Patient-reported outcomes
- for health-related quality of life, 295
- regulation of, 372
Payer perspective, of pharmacogenetic testing, 9
Pharmaceutical drugs. See also specific drugs
- formulary development, 382
- marketing. See Drug promotions
- pricing, 8
Pharmacoeconomics, in formulary development, 297, 382
Pharmacogenetic testing, for drug development, 8
PhRMA Health Outcomes Committee Workshop, on HRQL regulatory issues, 14
Subject Index

Platelet aggregation inhibitors, economic evaluation in SOM development, 82
Poland, HBV alternative therapy, cost-effectiveness analysis of, 404
Post-hospitalization costs
  systemic fungal infections, 28
  vertebral fractures, 301
PPMQ (Patient Perception of Migraine Questionnaire), validation of, 421
Premature infants, respiratory syncytial virus infection costs, 55
Prescription drugs, formulary development, 297
Promotion. See Drug promotions
Psychometric validation, of Patient Perception of Migraine Questionnaire, 421
Public policy implications, of pharmacogenetic testing, 12

Q
Quality-adjusted life years (QALYs)
  gastroesophageal reflux disease, 312
  multiple sclerosis treatment, 44
  in women's health, 98
Quality of life assessment. See also Health-related quality of life
  comparative analysis for COPD, 436
  for gastroesophageal reflux disease, 106
Quality of life violations, FDA actions against, 389

R
Raloxifene, time-trade-off assessments, 98
R&D costs, revenue effects on, 6
Recurrence of stroke, in Stroke Outcome Model development, 82
Regence BlueShield, formulary development, 297
Relative risk, usage of, 430
Respiratory syncytial virus (RSV), hospitalization costs, 55

S
Sensitivity analysis
  fungal infection treatment costs, 26
  hepatitis B virus treatment costs, 404
  multiple sclerosis treatment costs, 44
  Sepsis coding, on UB-92 hospital bills, 79
St. George's Respiratory Questionnaire, for COPD quality-of-life assessment, 436
Statistical analysis
  comparative, for COPD quality-of-life assessments, 436
  in decision making, 430
  models of health status, 329
Stroke Outcome Model
costing methodology, 95
development of, 82
Survival data, metastatic colorectal cancer, 35

T
Thrombolytic therapy, economic evaluation in SOM development, 82
Time-trade-off assessments, in women's health, 98
Tobit model, vs. other HRQL measures, 329
Total operating net revenue, gene therapy, 5
Trastuzumab, pharmacogenetic testing, 11

U
UB-92 hospital bills, sepsis coding on, 79
UK health-care decision makers, usefulness of economic evaluations, 71
United Kingdom, Stroke Outcome Model development costing method, 95
United States, Stroke Outcome Model development costing method, 95

V
Validation, of Patient Perception of Migraine Questionnaire, 421
Vertebral fractures, inpatient hospital and post-acute care for, 301

W
Warning letters, analysis of, 389
Willingness-to-accept valuations, new innovations and, 67
Willingness-to-pay valuations, bias against new innovations, 67
Women, vertebral fractures, inpatient hospital and post-acute care for, 301
Women's health, time-trade-off assessments, 98
Work Productivity and Activity Impairment Questionnaire, for GERD, 106